AI-ACCELERATED DRUG DISCOVERY

Focused On-demand Library for Peroxisomal N(1)-acetyl-spermine/spermidine oxidase

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.

We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.

The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.

We use our state-of-the-art dedicated workflow for designing focused libraries for enzymes.

 Fig. 1. The sreening workflow of Receptor.AI

It includes in-depth molecular simulations of both the catalytic and allosteric binding pockets, with ensemble virtual screening focusing on their conformational flexibility. For modulators, the process includes considering the structural shifts due to reaction intermediates to boost activity and selectivity.

Several key aspects differentiate our library:

  • Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.
  • The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.
  • Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.
  • In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.

partner

Reaxense

upacc

Q6QHF9

UPID:

PAOX_HUMAN

Alternative names:

Polyamine oxidase

Alternative UPACC:

Q6QHF9; D3DXI6; Q5VWY0; Q6QHF5; Q6QHF6; Q6QHF7; Q6QHF8; Q6QHG0; Q6QHG1; Q6QHG2; Q6QHG3; Q6QHG4; Q6QHG5; Q6QHG6; Q86WP9; Q8N555; Q8NCX3

Background:

Peroxisomal N(1)-acetyl-spermine/spermidine oxidase, also known as Polyamine oxidase, is a flavoenzyme crucial in polyamine metabolism. It catalyzes the oxidation of N(1)-acetylspermine to spermidine, playing a pivotal role in polyamine back-conversion. This enzyme exhibits substrate specificity, favoring N(1)-acetylspermine and N(1)-acetylspermidine, and is integral in maintaining polyamine intracellular concentration.

Therapeutic significance:

Understanding the role of Peroxisomal N(1)-acetyl-spermine/spermidine oxidase could open doors to potential therapeutic strategies. Its involvement in polyamine metabolism and cellular sensitivity to antitumor polyamine analogs highlights its potential as a target in cancer therapy.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.